NPS

Filter by
 

Type of content

Publication date

Keywords

Target audience

Displaying 1 - 20 of 246
cover of New benzodiazepines in Europe – a review report
Publications

New benzodiazepines in Europe – a review

09.06.2021

This report provides a technical review of the current body of knowledge regarding new benzodiazepines that are monitored by the EU Early Warning System. The aims of this report are to strengthen situational awareness of new benzodiazepines in Europe, and to help stakeholders prepare for and...
yellow and white pills on a light grey background
News

New report highlights public health risks and increasing availability of ‘designer benzodiazepines’ in Europe

09.06.2021

New benzodiazepines, which are not controlled by international drug laws, come under the spotlight today in a new report released by the EU drugs agency (EMCDDA) (1). Often marketed as ‘designer benzodiazepines’, these substances are sold as ‘legal’ replacements for controlled benzodiazepines and...
Document library
Document library

Commission Delegated Directive (EU) 2021/802 on MDMB-4en-PINACA and 4F-MDMB-BICA

09.06.2021

This document links to the Commission Delegated Directive (EU) 2021/802 on MDMB-4en-PINACA and 4F-MDMB-BICA.
Timeline showing the year in which different new benzodiazepines were notified to the EU’s Early Warning System. The first, Phenazepam, was notified in 2007. A A total of 30 have been notified by 2020, most between the years 2014 and 2018.
Media library

Timeline of benzodiazepines formally notified to the EU Early Warning System for the first time, 2007–2020

09.06.2021

This timeline, showing when different benzodiazepines were formally notified to the EU Early Warning System for the first time, is taken from the publication New benzodiazepines in Europe – a review. The source data for the timeline may be found below. Yearr of notification Name 2007...
Events
Events

Second training Neptune: Guidance on the Management of Acute and Chronic Harms of Club Drugs and New Psychoactive Substances

05.05.2021

The EU4Monitoring Drugs (EU4MD) project of the EMCDDA is co-organising the Second training Neptune: Guidance on the Management of Acute and Chronic Harms of Club Drugs and New Psychoactive Substances...
Document library
Document library

DARK classics in chemical neuroscience: etonitazene and related benzimidazoles

24.03.2021
hand holding tube in laboratory
News

European Commission proposes to control two harmful new psychoactive substances

12.03.2021

Today, the European Commission has proposed to control two harmful new psychoactive substances (NPS) across the European Union. The substances in question — MDMB-4en-PINACA and 4F-MDMB-BICA — are both synthetic cannabinoids, which have been raising health concerns in Europe (1). The proposal to...
cover report 4F-MDMB-BICA
Publications

Risk assessment report on a new psychoactive substance: methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino}-3,3-dime- thylbutanoate (4F-MDMB-BICA) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)

12.03.2021

This risk assessment report presents the summary findings and the conclusion of the risk assessment carried out by the Scientific Committee of the EMCDDA on 4F-MDMB-BICA. The report is intended for policymakers and decision-makers in the institutions of the EU. Explanatory note: In the interests...
cover risk assessment MDMB-4en-PINACA
Publications

Risk Assessment Report on a new psychoactive substance: methyl 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazole-3-car- bonyl]amino}butanoate (MDMB-4en-PINACA) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)

12.03.2021

This risk assessment report presents the summary findings and the conclusion of the risk assessment carried out by the Scientific Committee of the EMCDDA on MDMB-4en- PINACA. The report is intended for policymakers and decision-makers in the institutions of the EU. Explanatory note: In the...
Cover page of risk assessment guidelines
Publications

EMCDDA operating guidelines for the risk assessment of new psychoactive substances

22.12.2020

The purpose of these guidelines is to ensure compliance with the scope and requirements of Regulation (EC) No 1920/2006 (as amended) and Council Framework Decision 2004/757/JHA (as amended) in respect to the risk assessment procedure for and reporting on new psychoactive substances. To...
Publications

EMCDDA technical report on the new psychoactive substance methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate (4F-MDMB-BICA)

21.12.2020

The purpose of this technical report is to provide an analysis of the available information on methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate (commonly known as 4F-MDMB-BICA), a synthetic receptor cannabinoid agonist that has recently emerged on the drug market in...
Publications

EMCDDA technical report on the new psychoactive substance methyl 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazole-3-carbonyl]amino}butanoate (MDMB-4en-PINACA)

21.12.2020

The purpose of this technical report is to provide an analysis of the available information on methyl 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazole-3-carbonyl]amino}butanoate (commonly known as MDMB-4en-PINACA), a synthetic cannabinoid receptor agonist that has recently emerged on the drug market...
Publication cover
Publications

New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic — an update from the EU Early Warning System

17.12.2020

In this update from the the EU Early Warning System aims to provide insights into what is happening with new psychoactive substances in Europe, based on data from the agency’s early warning and risk-assessment activities. The report covers the period until October 2020 and this year focuses on...
Events
Events

Meeting on the risk assessment of the new psychoactive substances 4F-MDMB-BICA and MDMB-4EN-PINACA

07.12.2020

The extended Scientific Committee of the EMCDDA meets on 7 December 2020 to examine the risk assessment by the EMCDDA on 4F-MDMB-BICA and MDMB-4EN-PINACA.
Events

VII International Conference on Novel Psychoactive Substances (NPS)

18.11.2020

The VII International Conference on Novel Psychoactive Substances (NPS) is jointly organised by the International Society for the Study of Emerging Drugs (ISSED), the United Nations Office on Drugs...
Publication cover
Publications

Report on the risk assessment of N,N-diethyl-2- [[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1Hbenzimidazole- 1-ethanamine (isotonitazene) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended)

13.11.2020

This publication presents the data and findings of the risk assessment on N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1- ethanamine (isotonitazene), carried out by the extended Scientific Committee of the EMCDDA on 26 May 2020. On the basis of the Risk Assessment...
Document library
Document library

Commission Delegated Directive on isotonitazene

13.11.2020

Isotonitazene is a synthetic opioid analgesic and is closely related to etonitazene and clonitazene, both of which are under international control under the 1961 United Nations Single Convention on...
Publications

EMCDDA initial report on the new psychoactive substance 4F-MDMB-BICA

03.11.2020

Methyl 2-({[1-(4-fluorobutyl)-1H-indol-3-yl]carbonyl}amino)-3,3-dimethylbutanoate (4F-MDMB-BICA) is a synthetic cannabinoid receptor agonist. Similar to other synthetic cannabinoids, it is sold as a ‘legal’ replacement for cannabis. Because of their high potency, synthetic cannabinoids can pose a...
Publications

EMCDDA initial report on the new psychoactive substance MDMB-4en-PINACA

03.11.2020

Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate (MDMB-4en-PINACA) is a synthetic cannabinoid receptor agonist. Similar to other synthetic cannabinoids, it is sold as a ‘legal’ replacement for cannabis and controlled synthetic cannabinoids. Because of their high potency...
Publication thumbnail
Publications

EMCDDA technical report on the new psychoactive substance N,Ndiethyl- 2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1Hbenzimidazole- 1-ethanamine (isotonitazene)

03.06.2020

The purpose of this technical report is to provide an analysis of the available information on N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine (commonly known as isotonitazene), an opioid analgesic that has recently emerged on the drug market in Europe, to...